Could Primary Contact Physical Therapy Improve Emergency Department Care While Being Efficient? A 3-Month Cost-Utility Analysis
Abstract
OBJECTIVE: To evaluate the cost utility of 2 emergency department (ED) care models: management by an emergency physician (EP; usual care), and management by a primary contact physical therapist (PT) and an EP (PT + EP; intervention). DESIGN: Cost-utility analysis based on data collected during a pilot pragmatic randomized clinical trial over a 3-month period (NCT04009369). METHODS: We measured health-related quality of life (HRQoL) and health resource use at baseline, and 1 and 3 months, using the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L) and a standardized health care resource use questionnaire. Responses to the EQ-5D-5L were transformed into utility scores (Canadian conversion algorithm), and then into quality-adjusted life years (QALYs) using area-under-the-curve analyses. Costs and QALYs were used to derive incremental cost-effectiveness ratios for each perspective. We conducted a complete case analysis (main analysis), and missing data were imputed using multiple imputation (sensitivity analysis). RESULTS: After 3 months, participants managed by the PT + EP had a QALY gain of 0.195 (95% confidence interval [CI]: 0.179, 0.209), compared to 0.182 (95% CI: 0.168, 0.195) for those managed by the EP alone. The average total cost in the PT + EP group for the public payer was $469.23/patient (95% CI: $269.30, $708.85) and $878.37/patient for society (95% CI: $559.72, $1208.23), compared with $804.70/patient (95% CI: $225.58, $1972.78) and $1288.76/patient (95% CI:…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.